HBIO 8-K: SEC filing

Harvard Bioscience

Filed with the SEC on Nov 10, 2026 · accession 0001171843-26-007309

HBIO filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Harvard Bioscience filed an 8-K under Regulation FD to disclose that it is presenting a corporate slide presentation to the investment community, attached as Exhibit 99.1.

For details, click here →How to read a 8-K →

Key details

RegistrantHarvard Bioscience, Inc.

Chief financial officerMark Frost

✦ Ask GOAX AI about this filing — what it means for HBIO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for HBIO?

Click here

Frequently asked questions

What did HBIO file with the SEC on Nov 10, 2026?

HBIO filed a 8-K (SEC filing). Harvard Bioscience filed an 8-K under Regulation FD to disclose that it is presenting a corporate slide presentation to the investment community, attached as Exhibit 99.1.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other HBIO SEC filings

Get alerts when HBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

HBIO overview HBIO analysis HBIO news Latest SEC filings